1-(cyclopropylmethyl)-1-[[(1S,4S,5R)-3-[(2S)-2-[[(1S)-1-[(2,4-dioxo-3-azabicyclo[3.2.1]octan-3-yl)methyl]-2,2-dimethyl-propyl]carbamoylamino]-3,3-dimethyl-butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-4-carbonyl]amino]-3-[(1R)-1-phenylethyl]urea | 1187880-33-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-(cyclopropylmethyl)-1-[[(1S,4S,5R)-3-[(2S)-2-[[(1S)-1-[(2,4-dioxo-3-azabicyclo[3.2.1]octan-3-yl)methyl]-2,2-dimethyl-propyl]carbamoylamino]-3,3-dimethyl-butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-4-carbonyl]amino]-3-[(1R)-1-phenylethyl]urea
• 英文别名: 1-(cyclopropylmethyl)-1-[[(1R,2S,5S)-3-[(2S)-2-[[(2S)-1-(2,4-dioxo-3-azabicyclo[3.2.1]octan-3-yl)-3,3-dimethylbutan-2-yl]carbamoylamino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl]amino]-3-[(1R)-1-phenylethyl]urea
• CAS: 1187880-33-6
• 化学式: C₄₁H₆₁N₇O₆
• 分子量: 747.979
• InChiKey: CFGQHOYXHMEVGV-YWALTVCDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  54
• 可旋转键数：
  12
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  160
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  、 在 N-甲基吗啉 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 生成 1-(cyclopropylmethyl)-1-[[(1S,4S,5R)-3-[(2S)-2-[[(1S)-1-[(2,4-dioxo-3-azabicyclo[3.2.1]octan-3-yl)methyl]-2,2-dimethyl-propyl]carbamoylamino]-3,3-dimethyl-butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-4-carbonyl]amino]-3-[(1R)-1-phenylethyl]urea
  参考文献：
  名称：

  Potent aza-peptide derived inhibitors of HCV NS3 protease

  摘要：

  Chronic hepatitis C infection is the primary cause for cirrhosis of the liver and hepatocellular carcinoma leading to liver failure and transplantation. The etiological agent hepatitis C virus produces a single positive strand RNA that is processed further with the help of NS3 serine protease to produce mature virus. Inhibition of this protease can potentially be used to develop drugs for HCV infections. Boceprevir is a ketoamide derived novel inhibitor of HCV NS3 protease that has been progressed to clinical trials and proven to be efficacious in humans. Herein, we report our efforts in identifying an aza-peptide derivative as a potential second generation compound, that lacks electrophilic ketoamide group and are potent in enzyme and replicon assay. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.06.060